278
Views
14
CrossRef citations to date
0
Altmetric
Meta-Analyses

BMI levels with MS Bone mineral density levels in adults with multiple sclerosis: a meta-analysis

, , , &
Pages 904-912 | Received 10 Jun 2014, Accepted 12 Nov 2014, Published online: 18 Dec 2014

References

  • Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313):1221–31.
  • Shields AT, Chesnut CH, 3rd. Diagnosis of postmenopausal osteoporosis: reviews in endocrine and metabolic disorders. Rev Endocr Metab Disord 2001;2(1):23–33.
  • Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17(12):1726–33.
  • Cosman F, Nieves J, Komar L, et al. Fracture history and bone loss in patients with MS. Neurology 1998;51(4):1161–5.
  • Bazelier MT, van Staa TP, Uitdehaag BM, et al. Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology 2012;78(24):1967–73.
  • Bazelier MT, de Vries F, Bentzen J, et al. Incidence of fractures in patients with multiple sclerosis: the Danish National Health Registers. Mult Scler (Houndmills, Basingstoke, England) 2012;18(5):622–7.
  • Bazelier MT, van Staa T, Uitdehaag BM, et al. The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res 2011;26(9): 2271–9.
  • Formica CA, Cosman F, Nieves J, et al. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int 1997;61(2):129–33.
  • Sharts-Hopko NC, Smeltzer S. Perceptions of women with multiple sclerosis about osteoporosis follow-up. J Neurosci Nurs: J Am Assoc Neurosci Nurses 2004;36(4):189–94, 99.
  • Thorlund K, Imberger G, Johnston BC, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One 2012;7(7):e39471.
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–88.
  • Moghaddasi M, Aghaei M. Assessment of bone densitometry in Iranian patients with multiple sclerosis: a case-control study. Iran J Neurol 2013;12(1):9–14.
  • Ayatollahi A, Mohajeri-Tehrani MR, Nafissi S. Factors affecting bone mineral density in multiple sclerosis patients. Iran J Neurol 2013;12(1):19–22.
  • Zikan V, Tyblova M, Raska I, Jr., et al. Bone mineral density and body composition in men with multiple sclerosis chronically treated with low-dose glucocorticoids. Physiol Res 2012;61(4):405–17.
  • Sioka C, Papakonstantinou S, Fotopoulos A, et al. Bone mineral density in ambulatory patients with multiple sclerosis. Neurol Sci 2011;32(5):819–24.
  • Moen SM, Celius EG, Sandvik L, et al. Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome. Neurology 2011;77(2):151–7.
  • Dabbaghmanesh MH, Yousefipour GA. Bone loss with multiple sclerosis: effect of glucocorticoid use and functional status. Iran Red Crescent Med J 2011;13(1):9–14.
  • Assadi M, Salimipour H, Akbarzadeh S, et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS One 2011;6(9):e24240.
  • Terzi T, Terzi M, Tander B, Canturk F, Onar M. Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 2010;17(10):1260–4.
  • Ozgocmen S, Bulut S, Ilhan N, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 2005;23(4):309–13.
  • Tuzun S, Altintas A, Karacan I, et al. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler (Houndmills, Basingstoke, England) 2003;9(6):600–4.
  • Akpinar Z, Levendoglu F, Tokgoz S. Bone mineral density in patients with multiple sclerosis. Erciyes Tip Dergisi 2003;25(3):131–6.
  • Takata S, Yasui N. Disuse osteoporosis. The J Med Invest: JMI 2001;48(3–4):147–56.
  • Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. The New Engl J Med 2000;343(20):1430–8.
  • Ciccone A, Beretta S, Brusaferri F, et al. Corticosteroids for the long-term treatment in multiple sclerosis. The Cochrane Database Syst Rev 2008(1):CD006264.
  • Hachinski V. Steroid treatment in multiple sclerosis. Arch Neurol 1988;45(6):670.
  • Lloyd ME, Spector TD, Howard R. Osteoporosis in neurological disorders. J Neurol Neurosurg Psychiat 2000;68(5): 543–7.
  • Schwid SR, Goodman AD, Puzas JE, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996;53(8):753–7.
  • Weinstock-Guttman B, Gallagher E, Baier M, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 2004;10(2):170–5.
  • Gibson JG, Summers GD. Bone health in multiple sclerosis. Osteoporos Int 2011;22(12):2935–49.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.